Taiho, Cullinan report improved PFS in Phase III NSCLC trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported results from the Phase III REZILIENT3 trial, showing that zipalertinib combined with chemotherapy significantly improved PFS for patients with previously untreated, advanced NSCLC.
The post Taiho, Cullinan report improved PFS in Phase III NSCLC trial appeared first on Clinical Trials Arena .